EffectiveNess of a Multimodal preHAbilitation Program in patieNts With Bladder canCEr Undergoing Cystectomy
Launched by THE NETHERLANDS CANCER INSTITUTE · Jul 27, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The ENHANCE study is researching a special program designed to prepare patients with bladder cancer for surgery, specifically a procedure called radical cystectomy, which involves removing the bladder. This program includes various activities and support to help improve patients' overall health and well-being before and after their surgery. The study aims to find out if this program can reduce complications, shorten hospital stays, and improve physical fitness, mental health, and quality of life for patients.
To participate in this study, you must be at least 18 years old and have a confirmed diagnosis of bladder cancer. However, if you have serious mental health issues, are scheduled for surgery within the next three weeks, or cannot understand Dutch well enough to follow instructions, you may not be eligible. If you join, you can expect to engage in exercises and receive support that could help you manage your health better during this challenging time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically confirmed, primary, bladder cancer (cTa-4N0/N+M0),
- • Planned to undergo radical cystectomy,
- • Age ≥ 18 years.
- Exclusion Criteria:
- • Subjects with severe cognitive or psychiatric disorders,
- • Subjects who are operated within 3 weeks,
- • Subjects with insufficient command of the Dutch language, which precludes them from following study instructions or completing study questionnaires,
- • Subjects who have contraindications to safely perform exercise training or testing (i.e., CPET),
- • Subject who are unable or unwilling to participate in the intervention.
About The Netherlands Cancer Institute
The Netherlands Cancer Institute (NKI) is a leading research and treatment center dedicated to advancing the understanding and management of cancer. Renowned for its cutting-edge research, NKI fosters innovation in oncology through a multidisciplinary approach that integrates laboratory research, clinical trials, and patient care. With a commitment to translating scientific discoveries into effective therapies, the institute collaborates with national and international partners to enhance cancer treatment outcomes. NKI's state-of-the-art facilities and expertise in various cancer types position it as a pivotal contributor to the global fight against cancer, aiming to improve survival rates and quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Eindhoven, , Netherlands
Utrecht, , Netherlands
Groningen, , Netherlands
Rotterdam, , Netherlands
Nijmegen, , Netherlands
Alkmaar, , Netherlands
Maastricht, , Netherlands
Arnhem, , Netherlands
Utrecht, , Netherlands
Rotterdam, , Netherlands
Nijmegen, , Netherlands
Groningen, Hanzeplein 1, Netherlands
Utrecht, , Netherlands
Eindhoven, Michelangelolaan 2, Netherlands
Maastricht, , Netherlands
Arnhem, , Netherlands
Alkmaar, , Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials